Boston, MA, 04/02/2014 (medicalmarijuanareporter.com) – Easton Pharmaceuticals Inc (OTCMKTS:EAPH), a manufacturer of therapeutic and cosmetic healthcare products, has signed a letter of intent for the possible creation of a joint venture with another US company which would be a private medical marijuana company in the State of Colorado. The other company is a publicly traded company which is listed on the the OTCQB exchange. The joint-venture would buy an interest of finance the operations of a private Colorado grower. Any company which is not in resident in Colorado for at least two years cannot own in entirety the assets of any marijuana grower in the State.
Easton Pharmaceuticals Inc (OTCMKTS:EAPH) currently produces VIORRA which is an over-the-counter treatment for the restoration and improvement of vaginal moisture and elasticity which is believed to have a positive effect on the sexual arousal and desire of women. FSAD (Female Sexual Arousal Disorder); the term for these female conditions is conservatively estimated to have a world market which could be in the billions and VIORRA is a topical, daily-use product regarded by the FDA as generally safe. The company is now engaged in various initiatives to take advantage of the growth in the medical marijuana market.
It has now submitted a proposal to Vodis Innovative Pharmaceuticals and one other company who are both considered to possess the technology and the equipment for a partnership. The objective is to extract different ingredients from various strains of the marijuana plant which will allow Easton to research and develop its transdermal delivery system to produce various drugs based on marijuana which are known to be effective. Easton Pharmaceuticals Inc (OTCMKTS:EAPH) also believes that at some time in the future, transdermal patches will replace smoking and inhaling to deliver the ingredients in marijuana. It also believes that the United States will continue to progress towards the complete legalization of the substance. These plans are in the very early stages and this company is therefore a high-risk investment.